Absci-NameLogo.png
Absci to Participate in the Morgan Stanley 3rd Annual Life Sciences AI Summit
June 12, 2024 08:00 ET | Absci Corporation
VANCOUVER, Wash. and NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating...
Absci-NameLogo.png
Absci to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
May 28, 2024 08:00 ET | Absci Corporation
VANCOUVER, Wash. and NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating...
Absci-NameLogo.png
Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results
May 14, 2024 07:30 ET | Absci Corporation
Initiated IND-enabling studies for ABS-101 in February Continuing to advance ABS-201 and ABS-301 through preclinical studies VANCOUVER, Wash. and NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) --...
Absci-NameLogo.png
Absci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024
April 16, 2024 08:00 ET | Absci Corporation
VANCOUVER, Wash. and NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business...
Absci-NameLogo.png
Absci to Participate in the 23rd Annual Needham Virtual Healthcare Conference
March 28, 2024 16:05 ET | Absci Corporation
VANCOUVER, Wash. and NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be...
Absci-NameLogo.png
Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results
March 21, 2024 07:30 ET | Absci Corporation
Initiated IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody Entered into collaboration with AstraZeneca for up to $247M in deal value, plus royalties Strengthened...
Absci-NameLogo.png
Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
March 01, 2024 16:01 ET | Absci Corporation
VANCOUVER, Wash., March 01, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, today announced the closing of its underwritten...
Absci-NameLogo.png
Absci Announces Pricing of Public Offering of Common Stock
February 27, 2024 22:20 ET | Absci Corporation
VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, today announced the pricing of an underwritten...
Absci-NameLogo.png
Absci Announces Proposed Public Offering of Common Stock
February 27, 2024 16:01 ET | Absci Corporation
VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, announced today that it has commenced an...
Absci-NameLogo.png
Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI
February 21, 2024 07:30 ET | Absci Corporation
VANCOUVER, Wash. and NEW YORK, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the initiation of IND-enabling...